Can-Fite BioPharma (NYSE:CANF) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research report released on Monday. The brokerage issued a hold rating on the stock.

Can-Fite BioPharma Stock Performance

Can-Fite BioPharma stock opened at $1.98 on Monday. The stock has a fifty day moving average of $2.16 and a two-hundred day moving average of $2.12. The company has a market capitalization of $7.01 million, a price-to-earnings ratio of -1.11 and a beta of 1.53. Can-Fite BioPharma has a fifty-two week low of $1.68 and a fifty-two week high of $3.33.

Can-Fite BioPharma (NYSE:CANF) last released its quarterly earnings results on Thursday, March 28th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.04). The company had revenue of $0.16 million for the quarter, compared to analysts’ expectations of $0.20 million. Can-Fite BioPharma had a negative return on equity of 113.75% and a negative net margin of 1,027.46%. On average, analysts forecast that Can-Fite BioPharma will post -0.03 EPS for the current fiscal year.

Hedge Funds Weigh In On Can-Fite BioPharma

A hedge fund recently bought a new stake in Can-Fite BioPharma stock. Armistice Capital LLC acquired a new stake in Can-Fite BioPharma Ltd. (NYSE:CANF) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 154,363 shares of the company’s stock, valued at approximately $340,000. Armistice Capital LLC owned 4.36% of Can-Fite BioPharma as of its most recent SEC filing. Hedge funds and other institutional investors own 21.00% of the company’s stock.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.